# Phase 2 oropharyngeal cancer trials recruiting: 33 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 33 trials in phase 2 for oropharyngeal cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 oropharyngeal cancer trials: 33 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/oropharyngeal-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 33
- Recruiting or not yet: 33
- Read on: November 19, 2026

## Trials

The 25 newest of 33, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 18, 2026 | NCT07418034 | A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary... | University of Maryland, Baltimore | Phase 2 | Recruiting | Head and Neck Cancer, Head and Neck Squamous Cell Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal... | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07418034) |
| December 18, 2025 | NCT07290621 | Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer | University of Chicago | Phase 2 | Recruiting | Oropharyngeal Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07290621) |
| October 6, 2025 | NCT07209189 | Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch... | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | Recruiting | Head and Neck Cancer, Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharyngeal Cancer, Laryngeal Cancer, Sinonasal... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07209189) |
| September 29, 2025 | NCT07195734 | Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer | National Cancer Institute (NCI) | Phase 2 | Recruiting | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated... | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07195734) |
| September 17, 2025 | NCT07178301 | Evaluating a Decreased Dose of Radiation Therapy to the Elective Neck for the Treatment of HPV-Related Oropharyngeal Cancer, ENLIGHT Trial | Northwestern University | Phase 2 | Recruiting | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07178301) |
| July 14, 2025 | NCT07063212 | A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Squamous Cell Carcinoma of Head and Neck, Sinus Cancer, Nasal Cavity Cancer, Oral Cavity Cancer, Oropharynx Cancer... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07063212) |
| May 30, 2025 | NCT06997068 | Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States... | Mayo Clinic | Phase 2 | Recruiting | Metastatic Oral Cavity Carcinoma, Recurrent Oral Cavity Carcinoma, Stage IVC Lip and Oral Cavity Cancer AJCC v8, Head... | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06997068) |
| May 22, 2025 | NCT06984861 | A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Oropharyngeal Carcinoma | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06984861) |
| May 11, 2025 | NCT06965738 | Buccal Fat for Transoral Robotic Lateral Oropharyngectomy Defects to and Postoperative Pain | University Health Network, Toronto | Phase 2 | Not yet recruiting | Tonsil Neoplasm, Oropharynx Neoplasm, Transoral Robotic Surgery | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06965738) |
| November 22, 2024 | NCT06702033 | The Minimalist Trial-2 | Washington University School of Medicine | Phase 2 | Recruiting | HPV-Related Oropharynx Squamous Cell Carcinoma | 142 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06702033) |
| October 15, 2024 | NCT06636734 | Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial | Emory University | Phase 2 | Recruiting | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Neck... | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06636734) |
| August 29, 2024 | NCT06578871 | Surgery and Reducing Ionizing Radiation of the Unknown Primary | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Phase 2 | Not yet recruiting | Head and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06578871) |
| August 20, 2024 | NCT06563362 | Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck Squamous Cell Carcinoma | University of Zurich | Phase 2 | Recruiting | Oropharynx Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06563362) |
| August 1, 2024 | NCT06532279 | Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and... | NRG Oncology | Phase 2 | Recruiting | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated... | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06532279) |
| June 6, 2024 | NCT06445114 | Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer | Sponsor not shown (see the record) | Phase 2 | Recruiting | Oropharyngeal Cancer, Carcinoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06445114) |
| March 21, 2024 | NCT06323460 | Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer | Ohio State University Comprehensive Cancer Center | Phase 2 | Recruiting | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated... | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06323460) |
| February 12, 2024 | NCT06254911 | Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma | Emory University | Phase 2 | Recruiting | Oropharynx Cancer, Stage I | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06254911) |
| January 25, 2024 | NCT06223568 | Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly... | National Cancer Institute (NCI) | Phase 2 | Recruiting | Squamous Cell Carcinoma of the Head and Neck, Oropharynx, Human Papillomavirus Viruses, Drug Therapy, Cancer Vaccine | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06223568) |
| January 23, 2024 | NCT06219980 | SBRT Followed by Neoadjuvant Chemoimmunotherapy of Sindilizumab Plus Docetaxel and Cisplatin for Locoregionally Advanced Squamous Carcinoma... | Sun Yat-sen University | Phase 2 | Recruiting | SBRT | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06219980) |
| October 18, 2023 | NCT06088381 | Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL) | University of Maryland, Baltimore | Phase 2 | Recruiting | Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma, HPV... | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06088381) |
| June 8, 2023 | NCT05894083 | A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze) | University of Michigan Rogel Cancer Center | Phase 2 | Recruiting | Oropharyngeal Cancer, Squamous Cell Carcinoma of the Oropharynx | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05894083) |
| April 5, 2023 | NCT05800574 | Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer | Fox Chase Cancer Center | Phase 2 | Recruiting | Oropharynx Cancer | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05800574) |
| April 5, 2023 | NCT05799144 | pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer | Sponsor not shown (see the record) | Phase 2 | Recruiting | Metastatic Oropharyngeal Carcinoma, Recurrent Oropharyngeal Carcinoma | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05799144) |
| January 17, 2023 | NCT05686226 | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | Sponsor not shown (see the record) | Phase 2 | Recruiting | Cervical Cancer, Throat Cancer, Oropharynx Cancer, Anal Cancer, Vulva Cancer, Vaginal Cancer, Penile Cancer, Metastatic... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05686226) |
| September 15, 2022 | NCT05541016 | De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA | Mayo Clinic | Phase 2 | Recruiting | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated... | 455 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05541016) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Memorial Sloan Kettering Cancer Center | 4 |
| National Cancer Institute (NCI) | 3 |
| University of Maryland, Baltimore | 2 |
| Mayo Clinic | 2 |
| Emory University | 2 |
| NRG Oncology | 1 |
| Sun Yat-sen University | 1 |
| University of Zurich | 1 |
| Northwestern University | 1 |
| London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 1 |
| NYU Langone Health | 1 |
| Fox Chase Cancer Center | 1 |
| University of Michigan Rogel Cancer Center | 1 |
| University of Missouri-Columbia | 1 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1 |
| Centre hospitalier de l'Université de Montréal (CHUM) | 1 |
| Washington University School of Medicine | 1 |
| University Health Network, Toronto | 1 |
| University of Chicago | 1 |
| Ohio State University Comprehensive Cancer Center | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 28 |
| Canada | 3 |
| Australia | 2 |
| China | 1 |
| Switzerland | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Records storage companies in the United States](https://specstream.ai/data/businesses/records-storage-companies/united-states)
- [Home insurance agencies in the United States](https://specstream.ai/data/businesses/home-insurance-agencies/united-states)
- [Blueprint printers in the United States](https://specstream.ai/data/businesses/blueprint-printers/united-states)
- [Security companies in the United States](https://specstream.ai/data/businesses/security-companies/united-states)
- [Indonesian restaurants in the United States](https://specstream.ai/data/businesses/indonesian-restaurants/united-states)
- [Cambodian restaurants in the United States](https://specstream.ai/data/businesses/cambodian-restaurants/united-states)
